Martin H. Voss, MD

Articles

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

March 8th 2024

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

March 8th 2024

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

March 1st 2024

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1st 2024

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

February 23rd 2024

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

First-Line Treatments for Advanced Clear Cell RCC

February 23rd 2024

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC

December 6th 2019

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

Dr. Voss on the Case for Neoadjuvant Treatment in Kidney Cancer

February 6th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the case for neoadjuvant therapy in the treatment of kidney cancer.

Dr. Voss Discusses Treatment in the Neoadjuvant Setting for Kidney Cancer

January 16th 2018

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment in the neoadjuvant setting for patients with kidney cancer.

Dr. Voss on the Future of Clinical Trials for Kidney Cancer

December 26th 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of the clinical trial space for patients with kidney cancer.

Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC

December 1st 2017

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).

Dr. Voss on Bevacizumab With CRLX101 in Advanced RCC

June 25th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase II study examining bevacizumab combined with CRLX101 in patients with advanced renal cell carcinoma.

Dr. Voss on Early Efficacy Signals in DART Study for Advanced Kidney Cancer

March 12th 2015

Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses early efficacy signals in the phase I/II DART study.